Education
About Us
Working with TipRanks
Follow Us
Plus Therapeutics Inc (PSTV)
NASDAQ:PSTV
Earnings Data
Report Date
Apr 17, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.75Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: -32.89%
|Next Earnings Date:Apr 17, 2025
Earnings Call Sentiment|Positive
The earnings call presented a mix of promising clinical trial results, successful financing, and strategic acquisitions that position Plus Therapeutics for future growth. However, these positives were offset by an increase in operating loss and a decline in cash reserves. The overall sentiment leans towards optimism due to strong forward-looking developments.Company Guidance
In the recent Plus Therapeutics' Fourth Quarter and Full Year 2024 Results Conference Call, the company provided extensive guidance on its financial and clinical milestones. The company completed a $15 million equity financing and received $2 million in accelerated grant proceeds from CPRIT, securing funding through mid-2026. Key clinical updates included the completion of the ReSPECT-LM Phase 1 trial, establishing a recommended Phase 2 dose of 44 millicuries for their lead drug REYOBIQ, which showed promising safety and efficacy data. Plus Therapeutics plans to conduct an end-of-Phase 1 meeting with the FDA to finalize the path to approval, especially for LM related to breast cancer. Additionally, the company aims to advance its CNSide diagnostics platform, projecting significant market potential and a planned full launch within the year. Financially, the company reported a net loss of $13 million for 2024, compared to $13.3 million in 2023, and highlighted an expected 2025 grant revenue of $6 to $8 million.Successful Financing and Partnerships
Plus Therapeutics raised $15 million in an underwritten equity financing and received $2 million in accelerated grant proceeds from CPRIT. This strengthens the balance sheet and provides funding through mid-2026. Partnerships with SpectronRX, IsoTherapeutics, RadioMedix, and ABX were also announced to ensure supply chain management for REYOBIQ.
FDA Approvals and Designations
The company received FDA approval for orphan designation of REYOBIQ for LM due to lung cancer, adding to previous orphan and fast-track designations for breast cancer.
Positive Clinical Trial Results
ReSPECT-LM Phase 1 trial showed promising safety and efficacy data, with a recommended Phase 2 dose of 44 millicuries. Results indicated a median overall survival of nine months, compared to the historical four months.
CNSide Platform Acquisition and Launch
Plus Therapeutics acquired CNSide, a CNS cancer testing platform, to increase the market potential of REYOBIQ by 2-4 times. The assay is set to launch commercially this year, starting with a limited geographic introduction.
---
PSTV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PSTV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $1.52 | $1.16 | -23.68% |
| Nov 14, 2024 | $1.26 | $1.17 | -7.14% |
| Aug 14, 2024 | $1.42 | $1.40 | -1.41% |
| May 15, 2024 | $2.32 | $2.25 | -3.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Plus Therapeutics Inc (PSTV) report earnings?
Plus Therapeutics Inc (PSTV) is schdueled to report earning on Apr 17, 2025, TBA Not Confirmed.
What is Plus Therapeutics Inc (PSTV) earnings time?
Plus Therapeutics Inc (PSTV) earnings time is at Apr 17, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PSTV EPS forecast?
PSTV EPS forecast for the fiscal quarter 2025 (Q1) is -0.1.
---